ILLUMINA (ILMN) Company Report

Illumina reported strong Q4 2025 revenue of $1.16 billion, up 5% year-over-year, driven by 20% growth in clinical consumables revenue ex-China, and non-GAAP EPS of $1.35, up 42% year-over-year. For the full year 2025, the company returned to growth ex-China, expanded non-GAAP operating margins by 180 basis points, and grew non-GAAP EPS by 16% to $4.84.
For 2026, Illumina expects total company revenue of $4.5-$4.6 billion, representing reported growth of 4%-6%, with organic revenue growth ex-China of 2%-4%. Non-GAAP operating margins are projected to be 23.3%-23.5%, and non-GAAP EPS is guided between $5.05-$5.20, including $0.18 dilution from the SomaLogic acquisition.
The company completed the acquisition of SomaLogic in January 2026 for an upfront payment of $350 million, strengthening its position in multi-omics. Strategic pillars include core sequencing, scaling multi-omics, and expanding services, data, and software capabilities, highlighted by the launch of BioInsight and the Billion Cell Atlas for drug discovery.
Illumina generated $931 million in free cash flow for 2025 and returned approximately $740 million to shareholders through share repurchases, with $643 million remaining on its share repurchase authorization.

1 day ago

Transcript

Illumina Reports Q4 2025 Results and Provides FY26 Guidance

ILMN

Earnings

Guidance Update

M&A

Illumina reported Q4 2025 revenue of $1.16 billion, a 5% increase year-over-year (YoY), and non-GAAP diluted EPS of $1.35, a 42% increase YoY. The non-GAAP operating margin for the quarter was 23.7%, up 400 basis points YoY.
Key growth was driven by Clinical Sequencing Consumables revenue excluding China, which grew 20% YoY in Q4 2025. NovaSeq™ X placements exceeded 100 instruments in Q4 2025, with NovaSeq X accounting for 55% of high-throughput gigabases shipped and 51% of high-throughput consumables revenue.
The company closed the acquisition of SomaLogic in January 2026 for $350 million cash and up to $75 million in performance-based milestones, expecting SomaLogic to become profitable in 2027 on a non-GAAP operating income basis. For fiscal year 2026, Illumina provided guidance for total revenue between $4.50 billion and $4.60 billion (4% - 6% YoY growth) and non-GAAP diluted EPS between $5.05 and $5.20.

1 day ago

Presentation

Illumina Reports Strong Q4 and Full Year 2025 Results, Issues 2026 Guidance

ILMN

Earnings

Guidance Update

M&A

Illumina's Q4 2025 revenue reached $1.16 billion, marking a 5% year-over-year increase on a reported basis, with non-GAAP EPS of $1.35, representing a 42% growth year-over-year.
For the full year 2025, the company achieved 2% ex-China revenue growth, expanded non-GAAP operating margins by 180 basis points, and grew non-GAAP EPS by 16% to $4.84.
The company provided 2026 revenue guidance of $4.5-$4.6 billion, which translates to 4%-6% reported growth, and non-GAAP EPS guidance of $5.05-$5.20, including a $0.18 dilution from the SomaLogic acquisition.
Key drivers for 2025 performance included 20% ex-China growth in clinical consumables revenue in Q4 and strong NovaSeq X placements, with the acquisition of SomaLogic enhancing multi-omics capabilities.
Illumina anticipates double-digit to mid-teens clinical growth in 2026, while research and applied consumables revenue is projected to decline mid-to-high single-digits.

1 day ago

Transcript

Illumina Announces Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance

ILMN

Earnings

Guidance Update

M&A

Illumina reported Q4 2025 revenue of $1.16 billion, an increase of 5% year-over-year on a reported basis, with ex-China revenue growing 7%. Non-GAAP EPS for the quarter was $1.35, marking a 42% year-over-year increase.
For the full year 2025, Illumina achieved 2% ex-China revenue growth, expanded non-GAAP operating margins by 180 basis points, and grew non-GAAP EPS by 16% to $4.84. The company also generated $931 million in free cash flow and returned approximately $740 million to shareholders through share repurchases.
The company provided 2026 guidance, projecting total revenue of $4.5-$4.6 billion, representing 4%-6% reported growth. Organic revenue growth ex-China is anticipated to be 2%-4%, with clinical consumables expected to grow double-digit to mid-teens.
Illumina forecasts 2026 non-GAAP EPS between $5.05-$5.20, which includes an $0.18 dilution from the recently completed SomaLogic acquisition. Operating margins are expected to be 23.3%-23.5% in 2026.
The company remains confident in achieving its 2027 long-term targets of high single-digit growth and a 26% operating margin.

1 day ago

Transcript

Illumina Announces Q4 and Fiscal Year 2025 Financial Results and 2026 Guidance

ILMN

Earnings

Guidance Update

M&A

Illumina reported Q4 2025 revenue of $1.16 billion, a 5% increase from Q4 2024, with non-GAAP diluted EPS of $1.35.
For fiscal year 2025, the company's revenue was $4.34 billion, flat compared to 2024, and non-GAAP diluted EPS was $4.84.
The company provided fiscal year 2026 guidance, expecting total company revenue between $4.5 billion and $4.6 billion (4% - 6% growth) and non-GAAP diluted EPS in the range of $5.05 - $5.20.
Key announcements include the completion of the SomaLogic acquisition and the lifting of the Chinese Ministry of Commerce (MOFCOM) export ban on Illumina sequencers.

1 day ago

8-K

Illumina Reports Q4 and Fiscal Year 2025 Financial Results and Provides 2026 Guidance

ILMN

Earnings

Guidance Update

M&A

Illumina reported Q4 2025 revenue of $1.16 billion, a 5% increase from Q4 2024, and fiscal year 2025 revenue of $4.34 billion, which was flat compared to 2024.
Non-GAAP diluted EPS was $1.35 for Q4 2025 and $4.84 for fiscal year 2025.
For fiscal year 2026, Illumina expects total company revenue of $4.5 billion to $4.6 billion and non-GAAP diluted EPS in the range of $5.05 to $5.20.
The company completed the SomaLogic acquisition and announced that the Chinese Ministry of Commerce (MOFCOM) lifted the export ban on Illumina sequencers.

1 day ago

Press Release

Illumina Completes SomaLogic Acquisition

ILMN

M&A

New Projects/Investments

Illumina, Inc. completed its acquisition of SomaLogic on January 30, 2026.
The acquisition, funded with cash on hand, involved a purchase price of $350 million in cash at closing, plus up to $75 million in near-term performance-based milestones and royalties.
This deal expands Illumina's multiomics portfolio and strengthens its proteomics capabilities.
Illumina will discuss the financial implications of this transaction during its upcoming earnings call on February 5, 2026.

7 days ago

8-K

Illumina Completes SomaLogic Acquisition

ILMN

M&A

New Projects/Investments

Illumina, Inc. has completed its acquisition of SomaLogic, a leader in data-driven proteomics technology.
This acquisition expands Illumina's multiomics portfolio, strengthening its capabilities in delivering scalable insights across genomics and proteomics.
The deal involved $350 million in cash paid at closing, plus up to $75 million in near-term performance-based milestones and royalties, and was funded with cash on hand.
Illumina will discuss the financial implications of this transaction during its upcoming earnings call scheduled for February 5, 2026.

7 days ago

Press Release

illumin Announces Advertising Platform Upgrade

ILMN

Product Launch

New Projects/Investments

illumin Holdings Inc. (TSX: ILLM, OTCQB: ILLMF) announced a major upgrade to its advertising platform on January 27, 2026.
The upgraded platform is designed to deliver clear proof of programmatic performance, directly connecting advertising activity to business outcomes while budgets are active.
Key benefits for marketers include up to 50% extended audience reach, a 40% lift in Connected TV performance, and 25% lower retargeting costs, leading to a stronger return on ad spend.
New platform enhancements, such as Canvas, AI-powered Insights, and Impact, are integrated to facilitate in-market decision-making and continuous optimization of campaigns.
The updated platform is available immediately, with further enhancements planned throughout 2026.

Jan 27, 2026, 12:00 PM

Press Release

Illumina Secures CMS Reimbursement for TruSight Oncology Comprehensive

ILMN

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Illumina announced that its FDA-approved TruSight™ Oncology (TSO) Comprehensive test has secured reimbursement from the Centers for Medicare and Medicaid Services (CMS).
The reimbursement rate for the test is $2,989.55 per test, effective January 1, 2026, under the Clinical Laboratory Fee Schedule.
This decision is expected to expand access to comprehensive genomic profiling (CGP) for patients, empowering healthcare providers to deliver precision oncology insights.
Clinical markets were a key driver of growth, with clinical customers accounting for approximately 60% of Illumina's sequencing consumables revenue in fiscal year 2025.

Jan 20, 2026, 2:15 PM

Press Release

Fintool News

In-depth analysis and coverage of ILLUMINA.

Corporate

Illumina Launches Billion Cell Atlas: The Largest AI Drug Discovery Dataset Ever Built

Jan 13

View all news

Earnings Transcripts

Quarterly earnings call transcripts for ILLUMINA.

Q4 2025

Feb 5, 2026

→

Q3 2025

Oct 30, 2025

→

Q2 2025

Jul 31, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Jacob Thaysen say about margins?What are ILLUMINA's strategic priorities?How is ILLUMINA positioned vs competitors?How did ILLUMINA do last quarter?

ILLUMINA (ILMN)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Q4 2025

Executives

Jacob Thaysen

Ankur Dhingra

Everett Cunningham

Kevin Pegels

Scott Davies

Steve Barnard

Board Members

Anna Richo

Caroline Dorsa

Frances Arnold

Gary Guthart

Keith Meister

Philip Schiller

Robert Epstein

Scott Gottlieb

Scott Ullem

Susan Siegel

Analyst Coverage

David Westenberg

Tycho Peterson

Vijay Kumar

Puneet Souda

Kyle Mikson

Conor Noel McNamara

Dan Arias

Daniel Brennan

Douglas Schenkel

Doug Schenkel

Jack Meehan

Michael Ryskin

Casey Woodring

Daniel Arias

Patrick Donnelly

Subbu Nambiar

Subhalaxmi Nambi

Sung Ji Nam

Ben Miller

Daniel Leonard

Eve Burstein

Rachel Vatnsdal

Rachel Vatnsdal Olson

Subbu Nambi

Tejas Savant

Latest news

Fintool News

Illumina Launches Billion Cell Atlas: The Largest AI Drug Discovery Dataset Ever Built

Earnings Transcripts

Q4 2025

Q3 2025

Q2 2025

Ask Fintool AI Agent